Eli Lilly (LLY) emerges among the top performers in Big Pharma in 2024 with obesity drug success, while Novo Nordisk (NVO) ...

Both companies are longtime leaders in the pharmaceutical industry and have been making breakthroughs and delivering ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

Although Novo will still make a mind-blowing amount of money from its existing obesity drugs in the coming years (its ...

In a new study, an experimental obesity drug from Novo Nordisk called CagriSema allowed people to lose more than 20% of their ...

Alzheimer's, addiction, cardiovascular diseases, kidney disorders, sleep apnoea, diabetes, obesity, and overweight.

EUROPE’S Stoxx 600 index clocked its first weekly advance in three on Friday (Dec 27), boosted by advancing healthcare and ...

These projects align with Novo's strategic focus on 'drill ready' exploration targets with stand-alone development potential exceeding one million ounces (moz) of gold. HIGHLIGHTS Novo has ...

Tmall's shopping list for the pharmaceutical platform on Double Eleven! The transaction volume exceeded 100 million in just 2 minutes ...

In the case abovementioned ITAT Ahmedabad remanded the matter to CIT (A) after considering that assessee could not file evidence before CIT (A) in lack of service of notices.

The sale issue before the ITAT Delhi is whether assessment framed in second round (After remand back to AO by ITAT) under section 153A without getting approval under section 153D of Act, is ...

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 500.39% and ...